DiaMedica Inc., a Canadian biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders, announced the initiation of a type 1 diabetes program following the acquisition of Sanomune. The initiation of this program is based on encouraging preclinical results with DM-99, a naturally occurring protein that the company has previously...



